2044 related articles for article (PubMed ID: 24604920)
1. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
[TBL] [Abstract][Full Text] [Related]
2. Agomelatine versus other antidepressive agents for major depression.
Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
Cochrane Database Syst Rev; 2013 Dec; (12):CD008851. PubMed ID: 24343836
[TBL] [Abstract][Full Text] [Related]
3. Vortioxetine for depression in adults.
Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
[TBL] [Abstract][Full Text] [Related]
4. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control.
Kasper S; Corruble E; Hale A; Lemoine P; Montgomery SA; Quera-Salva MA
Int Clin Psychopharmacol; 2013 Jan; 28(1):12-9. PubMed ID: 23023074
[TBL] [Abstract][Full Text] [Related]
5. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials.
Machado M; Einarson TR
J Clin Pharm Ther; 2010 Apr; 35(2):177-88. PubMed ID: 20456736
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Guaiana G; Meader N; Barbui C; Davies SJ; Furukawa TA; Imai H; Dias S; Caldwell DM; Koesters M; Tajika A; Bighelli I; Pompoli A; Cipriani A; Dawson S; Robertson L
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD012729. PubMed ID: 38014714
[TBL] [Abstract][Full Text] [Related]
7. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
[TBL] [Abstract][Full Text] [Related]
8. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials.
Machado M; Iskedjian M; Ruiz I; Einarson TR
Curr Med Res Opin; 2006 Sep; 22(9):1825-37. PubMed ID: 16968586
[TBL] [Abstract][Full Text] [Related]
9. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
[TBL] [Abstract][Full Text] [Related]
10. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
[TBL] [Abstract][Full Text] [Related]
11. Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults.
Sobieraj DM; Martinez BK; Hernandez AV; Coleman CI; Ross JS; Berg KM; Steffens DC; Baker WL
J Am Geriatr Soc; 2019 Aug; 67(8):1571-1581. PubMed ID: 31140587
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
Papakostas GI; Fava M
Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534
[TBL] [Abstract][Full Text] [Related]
13. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Effects of Antidepressants with Different Mechanisms of Action on Efficacy, Cognitive Functions and Side Effects.
Erdoğan Ç; Özdemir Rezaki H; Koçak OM; Buturak ŞV
Turk Psikiyatri Derg; 2020; 31(2):90-98. PubMed ID: 32594496
[TBL] [Abstract][Full Text] [Related]
15. [Agomelatine in the treatment of major depressive disorder: assessment of the efficacy and tolerability].
Filippova NV; Barylnik YB; Shuldyakov AA; Antonova AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(5):154-161. PubMed ID: 31317905
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant efficacy of Agomelatine: Meta-analysis of placebo controlled and active comparator studies.
Maddukuri RK; Hema C; Sri Tejaswi K; Venkata Mounika M; Vegesana BP
Asian J Psychiatr; 2021 Nov; 65():102866. PubMed ID: 34592623
[TBL] [Abstract][Full Text] [Related]
17. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
[TBL] [Abstract][Full Text] [Related]
18. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
Demyttenaere K; Corruble E; Hale A; Quera-Salva MA; Picarel-Blanchot F; Kasper S
CNS Spectr; 2013 Jun; 18(3):163-70. PubMed ID: 23472671
[TBL] [Abstract][Full Text] [Related]
19. Prediction of early improvement of major depressive disorder to antidepressant medication in adolescents with radiomics analysis after ComBat harmonization based on multiscale structural MRI.
Ma H; Zhang D; Wang Y; Ding Y; Yang J; Li K
BMC Psychiatry; 2023 Jun; 23(1):466. PubMed ID: 37365541
[TBL] [Abstract][Full Text] [Related]
20. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
